Silverback Therapeutics in Supply Agreement for Libtayo With Regeneron
July 07 2021 - 7:26AM
Dow Jones News
By Chris Wack
Silverback Therapeutics Inc. said it is in a clinical supply
agreement with Regeneron Pharmaceuticals Inc. for Libtayo
cemiplimab.
Silverback said the supply agreement supports the evaluation of
Libtayo, a PD-1 inhibitor, in combination with SBT6050, a targeted
immuno-oncology agent designed to direct a TLR8 agonist
linker-payload to activate myeloid cells in tumors expressing
moderate to high levels of HER2.
In the first quarter of 2021, Silverback began treatment in Part
3 of the Phase 1/1b study to evaluate the activity of SBT6050 in
combination with a PD-1 inhibitor in dose escalation.
Under the terms of the agreement, Silverback will expand the
ongoing Phase 1/1b trial to evaluate the combination of SBT6050 and
Libtayo in tumor-specific dose expansion cohorts, initially in
HER2-expressing non small cell lung cancer and gastric cancer.
Silverback shares were up 25% to $35.69 in premarket
trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 07, 2021 08:14 ET (12:14 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Apr 2024 to May 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From May 2023 to May 2024